Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma

NCT07648823 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

5

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Glioblastoma (WHO-Grade IV Glioma)
Recurrent Glioblastoma
Glioblastoma (GBM)
Recurrent Glioblastoma IDH Wildtype

Interventions

DRUG: [177Lu]Lu-XT771

Sponsor

Beijing Tiantan Hospital